Larvol Delta - Mateons-phase-2-global-study-for-OT101-TGF-inhibitor-against-Covid19-cleared-for-patient-enrollment-in-Argentina

trabedersen (OT-101) - Autotelic, Mateon Therapeutics

https://www.globenewswire.com/news-release/2020/10/19/2110287/0/en/MATEON-S-PHASE-2-GLOBAL-STUDY-FOR-OT-101-TGF-%CE%B2-INHIBITOR-AGAINST-COVID-19-CLEARED-FOR-PATIENT-ENROLLMENT-IN-ARGENTINA.html

Oct 19, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next